

## BCG vaccine

## Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

## Indications

Need for immunization against tuberculosis

## Japanese encephalitis vaccine

## Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

## Indications

Need for immunization against certain single viral diseases

## Adalimumab

## Section

Immunomodulators for non-malignant disease

Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Medicines for juvenile joint diseases

Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

## Indications

Axial spondyloarthritis

Crohn disease site

Rheumatoid arthritis

Juvenile idiopathic arthritis

## Ansuvimab

## Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 400 mg powder for injection

## Indications

Ebola virus disease

## Anti-D immunoglobulin

## Section

Human immunoglobulins

Parenteral > General injections > IV: 250 µg in single-dose vial

Parenteral > General injections > IM: 250 µg in single-dose vial

## Indications

Rh incompatibility reaction

Maternal care for red cell antibodies

## Anti-rabies immunoglobulin

### Section

Human immunoglobulins

Parenteral > General injections > IM: 150 IU per mL in vial

Parenteral > Locoregional injections > Other: 150 IU per mL in vial

### Indications

Rabies

## Anti-rabies virus monoclonal antibodies

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)

### Indications

Rabies

## Anti-tetanus immunoglobulin

### Section

Human immunoglobulins

Parenteral > General injections > IM: 500 IU in vial

### Indications

Tetanus

## Antivenom immunoglobulin

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

Parenteral > General injections > IV:

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Asparaginase

### Section

Cytotoxic medicines

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

## Atezolizumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

### Indications

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab for

Adenocarcinoma of stomach

Hepatocellular carcinoma of liver

## Atoltivimab + maftivimab + odesivimab

### Section

#### Medicines for Ebola virus disease

Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

### Indications

Ebola virus disease

## Axicabtagene ciloleucel

### Section

#### Antineoplastics and supportive medicines

Cell suspension for infusion:  $2 \times 10^6$  anti-CD19 CAR-positive viable T-cells per kg of body weight.

### Indications

Diffuse large B-cell lymphomas

## Beractant

### Section

#### Medicines administered to the neonate [c]

Respiratory > Suspension: 25 mg per mL for intratracheal instillation

### Indications

Respiratory distress syndrome of newborn

## Bevacizumab

### Section

#### Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

#### Immunomodulators

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

### Indications

Age related macular degeneration

Hepatocellular carcinoma of liver

## Cemiplimab

### Section

Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

### Indications

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab for

Adenocarcinoma of stomach

## Certolizumab pegol

### Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

### Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

## Cholera vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against cholera alone

## Coagulation factor IX complex

### Section

Coagulation factors

### Indications

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Haemophilia B

## Coagulation factor IX, plasma-derived

### Section

#### Coagulation factors

Parenteral > General injections > IV: 500 IU in vial powder for injection;  
1000 IU in vial powder for injection

### Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Haemophilia B

## Coagulation factor VIII, plasma-derived

### Section

#### Coagulation factors

Parenteral > General injections > IV: 250 IU in vial powder for injection;  
500 IU in vial powder for injection; 1000 IU in vial powder for injection

### Indications

Haemophilia A

## Cryoprecipitate (not pathogen-reduced)

### Section

#### Blood and blood components

### Indications

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Obstetric haemorrhage

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Haemophilia A

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Von Willebrand disease

## Cryoprecipitate (pathogen-reduced)

### Section

#### Blood and blood components

Injection: frozen liquid in bag or lyophilized powder in vial containing:

> 50 IU Factor VIII

> 100 IU vWF

> 140 mg clottable fibrinogen per unit

### Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Obstetric haemorrhage

Haemophilia A

Von Willebrand disease

## Dalteparin

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to enoxaparin for

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin for

Venous thromboembolism

## Darbepoetin alfa

### Section

Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Supportive medicines

Therapeutic equivalent to erythropoiesis-stimulating agents for

Drug-induced aplastic anaemia

## Dengue vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Diphtheria antitoxin

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial

### Indications

Need for immunization against diphtheria alone

## Diphtheria vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against diphtheria alone

## Dostarlimab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

### Indications

Other specified malignant neoplasms of corpus uteri

## Dulaglutide

### Section

#### Hypoglycaemic agents

### Indications

Therapeutic equivalent to semaglutide for

Type 2 diabetes mellitus

## Durvalumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

### Indications

Hepatocellular carcinoma of liver

Malignant neoplasms of biliary tract, distal bile duct

Malignant neoplasm of intrahepatic bile ducts

Malignant neoplasms of gallbladder

Malignant neoplasms of proximal biliary tract, cystic duct

## Emicizumab

### Section

#### Medicines affecting coagulation

Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial

### Indications

Haemophilia A

## Enoxaparin

### Section

#### Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

### Indications

Acute ischaemic heart disease

Venous thromboembolism

## Epoetin alfa

### Section

Antianaemia medicines

Supportive medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Therapeutic equivalent to erythropoiesis-stimulating agents for

Drug-induced aplastic anaemia

## Epoetin beta

### Section

Antianaemia medicines

Supportive medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Therapeutic equivalent to erythropoiesis-stimulating agents for

Drug-induced aplastic anaemia

## Epoetin theta

### Section

Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

## Eptinezumab

### Section

Medicines for migraine prophylaxis

### Indications

Therapeutic equivalent to fremanezumab for

Chronic migraine

## Equine rabies immunoglobulin

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies  
Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial;  
200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial

### Indications

Rabies

## Erenumab

### Section

Medicines for migraine prophylaxis

### Indications

Therapeutic equivalent to [fremanezumab](#) for

Chronic migraine

## Erythropoiesis-stimulating agents

### Section

#### Antianaemia medicines

Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

#### Supportive medicines

Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

### Indications

Anaemia due to chronic disease

Drug-induced aplastic anaemia

## Etanercept

### Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

### Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

## Filgrastim

### Section

#### Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

### Indications

Acquired neutropaenia

## Fremanezumab

### Section

#### Medicines for migraine prophylaxis

Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe

### Indications

Chronic migraine

## Fresh-frozen plasma

### Section

#### Blood and blood components

Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Galcanezumab

### Section

#### Medicines for migraine prophylaxis

### Indications

Therapeutic equivalent to fremanezumab for

Chronic migraine

## Golimumab

### Section

#### Immunomodulators for non-malignant disease

### Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

#### Medicines for juvenile joint diseases

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

## Haemophilus influenzae type b vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against single bacterial diseases

## Hepatitis A vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against viral hepatitis

## Hepatitis B vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against viral hepatitis

## Human papilloma virus (HPV) vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Infliximab

### Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

### Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

## Influenza vaccine (seasonal)

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against influenza

## Insulin (analogue, long-acting)

### Section

Insulins

Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution

### Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

## Insulin (human, intermediate-acting)

### Section

Insulins

Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

### Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

## Insulin (human, short-acting)

### Section

Insulins

Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution

### Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

## Insulin degludec

### Section

Insulins

### Indications

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

## Insulin detemir

### Section

Insulins

### Indications

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

## Insulin glargine

### Section

Insulins

### Indications

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

## Ipilimumab

### Section

Immunomodulators

Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Melanoma of skin

## Liraglutide

### Section

Hypoglycaemic agents

### Indications

Therapeutic equivalent to semaglutide for

Type 2 diabetes mellitus

## Lisocabtagene maraleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

## Measles vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against measles alone

## Meningococcal meningitis vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against single bacterial diseases

## Methoxy polyethylene glycol-epoetin beta

### Section

Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

## Mumps vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against mumps alone

## Nadroparin

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to enoxaparin for

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin for

Venous thromboembolism

## Nivolumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Adenocarcinoma of oesophagogastric junction

Adenocarcinoma of stomach

## Normal immunoglobulin

### Section

#### Human immunoglobulins

Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Parenteral > General injections > IM: 16% protein solution

Parenteral > General injections > SC: 15% protein solution; 16% protein solution

#### Medicines for Guillain-Barré syndrome

Parenteral > General injections > IV: 5% protein solution; 10% protein solution

### Indications

Primary immunodeficiencies

Langerhans cell histiocytosis

Mucocutaneous lymph node syndrome

Acute inflammatory demyelinating polyneuropathy

## Ocrelizumab

### Section

#### Medicines for multiple sclerosis

Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution

### Indications

Multiple sclerosis

## Pegaspargase

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

### Indications

Lymphoid leukaemia, not elsewhere classified

## Pegfilgrastim

### Section

#### Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

### Indications

Acquired neutropaenia

## Pegylated interferon alfa (2a)

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C  
Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pegylated interferon alfa (2b)

### Section

Medicines for hepatitis C > Other antivirals for hepatitis C  
Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pembrolizumab

### Section

Immunomodulators  
Parenteral > General injections > IV: 25 mg per mL in 4 mL vial  
Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection  
Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

### Indications

Other specified malignant neoplasms of large intestine

Other specified malignant neoplasms of bronchus or lung

Adenocarcinoma of stomach

Squamous cell carcinoma of hypopharynx and variants

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx

Squamous cell carcinoma of oropharynx

Carcinoma of breast, specialised type

Squamous cell carcinoma of nasopharynx

Squamous cell carcinoma of oesophagus

Malignant neoplasms of oesophagogastric junction

Therapeutic equivalent to nivolumab for

Melanoma of skin

## Pertussis vaccine

### Section

Immunologicals > Vaccines  
All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against pertussis alone

## Platelets

### Section

Blood and blood components

Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Pneumococcal vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against single bacterial diseases

## Poliomyelitis vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against poliomyelitis

## Rabies vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against rabies

## Red blood cells

### Section

Blood and blood components

Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Rituximab

### Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

### Indications

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

Medicines for multiple sclerosis

Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

Multiple sclerosis

## Rotavirus vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Rubella vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against rubella alone

## Semaglutide

### Section

Hypoglycaemic agents

Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL

### Indications

Type 2 diabetes mellitus

## Tetanus vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against tetanus alone

## Tick-borne encephalitis vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against arthropod-borne viral encephalitis

## Tirzepatide

### Section

Hypoglycaemic agents

### Indications

Therapeutic equivalent to semaglutide for

Type 2 diabetes mellitus

## Tisagenlecleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

## Tislelizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

## Toripalimab

### Section

Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

### Indications

Malignant neoplasms of nasopharynx

Squamous cell carcinoma of oesophagus

## Trastuzumab

### Section

Targeted therapies

Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

### Indications

Carcinoma of breast, specialised type

## Tremelimumab

### Section

Immunomodulators

Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

### Indications

Hepatocellular carcinoma of liver

Other specified malignant neoplasms of bronchus or lung

## Typhoid vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against typhoid-paratyphoid alone

## Ustekinumab

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation  
Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen

### Indications

Psoriasis of unspecified type

## Varicella vaccine

### Section

Immunologicals > Vaccines  
All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Whole blood

### Section

Blood and blood components  
Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Yellow fever vaccine

### Section

Immunologicals > Vaccines  
All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases